Lingohr Asset Management GmbH Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Lingohr Asset Management GmbH bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 9,610 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pacer Advisors Inc. boosted its stake in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares in the last quarter. Boston Partners lifted its holdings in shares of Catalyst Pharmaceuticals by 1.3% during the fourth quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock valued at $27,325,000 after purchasing an additional 16,601 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after purchasing an additional 79,182 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in shares of Catalyst Pharmaceuticals by 74.3% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock worth $15,421,000 after buying an additional 312,000 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Catalyst Pharmaceuticals by 1.3% during the 4th quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company’s stock valued at $15,100,000 after buying an additional 9,194 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Price Performance

CPRX stock opened at $22.60 on Thursday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $24.64. The company has a market cap of $2.74 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock’s fifty day moving average price is $22.34 and its 200-day moving average price is $21.57.

Wall Street Analysts Forecast Growth

CPRX has been the topic of several analyst reports. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Bank of America reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird increased their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. Finally, Stephens restated an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.50.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.